|
01 Feb 2021 |
Janssen Announces CAR-T Therapy Ciltacabtagene Autoleucel (Cilta-cel) Accepted for Accelerated Assessment in Europe for the Treatment of Patients with Heavily Pretreated Multiple Myeloma
|
|
29 Jan 2021 |
Bellicum Reports FDA Lifted Clinical Hold on BPX-601 Phase 1/2 Clinical Trial
|
|
29 Jan 2021 |
Focus on solid tumors - Discontinuation of MDG1021 development program
|
|
29 Jan 2021 |
Vertex Announces FDA Clearance of Investigational New Drug (IND) Application for VX-880, a Novel Cell Therapy for the Treatment of Type 1 Diabetes (T1D)
|
|
28 Jan 2021 |
Passage Bio Receives FDA Clearance of IND Application for PBFT02 Gene Therapy Candidate for Treatment of Patients with Frontotemporal Dementia with Granulin Mutations
|
|
28 Jan 2021 |
AskBio Adds CNS Gene Therapy Programs in Parkinson’s Disease and Multiple System Atrophy
|
|
28 Jan 2021 |
Artiva Biotherapeutics Announces Exclusive Worldwide Collaboration and License Agreement with Merck to Develop Candidate CAR-NK Cell Therapies
|
|
22 Jan 2021 |
YESCARTA® Approved in Japan for Treatment of Patients with Relapsed/Refractory Large B-Cell Lymphomas
|
|
21 Jan 2021 |
Ultragenyx Announces FDA Clearance of Investigational New Drug (IND) Application for UX701, a New Gene Therapy for the Treatment of Wilson Disease
|
|
21 Jan 2021 |
Kuur Therapeutics Announces Interim Clinical Data Supporting CAR-NKT Cell Therapy Platform
|
|
20 Jan 2021 |
T-Cure Bioscience and Immunotech Biopharm Ltd Announce License Agreement for Novel HERV-E T Cell Receptor Therapy
|
|
20 Jan 2021 |
Caladrius Biosciences Treats First Patient in the Phase 2b FREEDOM Trial of CLBS16 for the Treatment of Coronary Microvascular Dysfunction
|
|
20 Jan 2021 |
Histogen Reports FDA Clinical Hold for Planned Phase 1/2 Trial of HST-003 for Knee Cartilage Regeneration
|
|
20 Jan 2021 |
Kiromic Announces the Completion of its GMP Manufacturing Facility in Houston, Texas, to Support the Manufacturing of the First In-Human Allogenic CAR-T Trial
|
|
20 Jan 2021 |
Precision BioSciences Announces FDA Accepts IND for PBCAR19B, a Next-Generation, Stealth Cell, CD19 Allogeneic CAR T Candidate for Non-Hodgkin Lymphoma
|
|
18 Jan 2021 |
Ixaka (formerly Rexgenero) launches as an integrated cell and gene therapy company
|
|
18 Jan 2021 |
Sirnaomics Announces First Patient Dosed In Phase 2a Study of STP705 for Treatment of Cutaneous Basal Cell Carcinoma
|
|
18 Jan 2021 |
ViGeneron announces research collaboration with Daiichi Sankyo to evaluate vgAAV for novel ophthalmic gene therapy
|
|
14 Jan 2021 |
Vor Announces FDA Clearance of IND Application for VOR33
|
|
13 Jan 2021 |
Cytovia Therapeutics Partners with National Cancer Institute to Develop Novel Gene-Edited, iPSC-Derived GPC3 CAR NK Cells for the Treatment of Solid Tumors
|
|
13 Jan 2021 |
KSQ Therapeutics and Takeda Enter Broad Strategic Collaboration to Research, Develop and Commercialize Novel Immuno-Oncology Therapies
|
|
13 Jan 2021 |
Jasper Therapeutics and Graphite Bio Announce Collaboration to Evaluate JSP191 as Conditioning Regimen for Novel Gene Replacement Therapy in Patients with XSCID
|
|
13 Jan 2021 |
Daiichi Sankyo Announces the Results Summary of Phase 1/2 Clinical Trial in Japan for DS-5141
|
|
12 Jan 2021 |
Verve Therapeutics Announces Data Demonstrating Durable LDL Cholesterol Lowering After a One-Time Gene Editing Treatment in Non-Human Primates
|
|
12 Jan 2021 |
Bone Therapeutics treats first patient in ALLOB Phase IIb tibial fracture study
|
